T1	Participants 64 123	patients with mild-to-moderately-active ulcerative colitis:
T2	Participants 465 676	patients with symptoms of acute UC and a baseline Modified Mayo Disease Activity Index (MMDAI) score between 6 and 10, inclusive, with a subscale rating of > or =2 for both rectal bleeding and mucosal appearance
T3	Participants 1064 1106	249 patients (166 balsalazide, 83 placebo)
